182268-26-4

Upstream product

• 22509-74-6 N-ethoxycarbonylphthalimide 
• 182268-32-2 benzyl (2S)-2-[(3R,4S)-4-chloro-3-phthalimido-2-oxazetidin-1-yl]-2-(1-chlorothio-1-methylethyl)-acetate 
• 20425-27-8 (2S,5R,6R)-6-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 
• 66363-43-7 (2S,5R,6S)-benzyl 6-(1,3-dioxoisoindolin-2-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 
• 551-16-6 6-Aminopenicillanic Acid 
• 59034-26-3 (2S,5R,6R)-benzyl 6-(1,3-dioxoisoindolin-2-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 
• 182268-25-3 benzyl (2S)-2-[(3S,4R)-4-chloro-3-phthalimido-2-oxazetidin-1-yl]-2-(1-chlorothio-1-methylethyl)-acetate 

Downstream Products

• 182268-27-5 benzyl (-)-(2S,4S,5S,6S)-3,3-dimethyl-7-oxo-6-phthalimido-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4-oxide 
• 182268-30-0 benzyl (-)-(6S,7S)-3-methyl-8-oxo-7-phenylacetamido-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 182268-28-6 benzyl (-)-(6S,7S)-7-amino-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 182186-35-2 (6S,7S)-benzyl 7-(1,3-dioxoisoindolin-2-yl)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 182268-29-7 benzyl (-)-(6S,7S)-3-methyl-8-oxo-7-phenoxyacetamido-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 1316164-04-1 2-[(2S,5S,6S)-2-(benzyloxycarbonyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-6-ylcarbamoyl]benzoic acid 
• 1316164-11-0 benzyl (2S,5S,6S)-3,3-dimethyl-7-oxo-6-phthalisoimido-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 
• 1316164-13-2 benzyl (2S,5S,6S)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 
• 1316164-18-7 benzyl (2S,5S,6S)-6-[(N-decanoyl-L-prolyl-L-threonyl-L-alanyl-L-asparaginyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylate 

Relevant academic research and scientific papers

PEPTIDE ANTIBIOTICS AND METHODS OF USE THEREOF

The invention features peptide antibiotic compositions and methods of using such compositions for the treatment of bacterial infections (e.g., vancomycin resistant infections).

Asymmetric synthesis of new β-lactam lipopeptides as bacterial signal peptidase i inhibitors

The transmembrane bacterial enzyme, signal peptidase I, is recognized as being a promising target for reducing the emergence of drug resistance. The asymmetric synthesis and the biological evaluation of original β-lactam lipopeptides have been performed t

Syntheses of (6S)-cephalosporins from 6-aminopenicillanic acid

Two practical routes to (6S,7S)-cephalosporins from 6-aminopenicillanic acid (6-APA) are described. In the first, 6-APA was converted to (2S,4S,5S,6S)-penicillin sulfoxide 49, which underwent Morin ring expansion to a protected (6S,7S)-cephem 50. In the s